HealthMore in Health→
FDA clears inhaled insulin for children ages 6 and up
Key Takeaways
- Afrezza is now approved for pediatric patients aged 6 and up.
- The inhaled insulin is designed for use at mealtime.
- The FDA cited the phase 3 INHALE-1 study and broader clinical evidence.
- The approval adds a non-injection option for some children with diabetes.
DE
DT Editorial Team··via medicalxpress.com
